Cell cultured-derived adjuvanted influenza vaccine (Grippol TC) - AbbVieAlternative Names: Grippol Neo; Grippol TC (cell-based adjuvanted seasonal vaccine) - Abbott
Latest Information Update: 11 Mar 2015
At a glance
- Originator Solvay Pharmaceuticals
- Developer AbbVie
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza virus infections